サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1588575

ELISA（酵素結合免疫吸着測定法）の世界市場：2024年～2031年

Global Enzyme-Linked Immunosorbent Assay Market - 2024-2031

出版日
ページ情報
英文 176 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
ELISA（酵素結合免疫吸着測定法）の世界市場：2024年～2031年
出版日: 2024年11月08日
発行: DataM Intelligence
ページ情報: 英文 176 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

概要

ELISA（酵素結合免疫吸着測定法）の世界市場は、2023年に21億4,000万米ドルに達し、2031年には33億5,000万米ドルに達し、予測期間2024年にはCAGR 5.8％で成長すると予測されています。

ELISA（酵素結合免疫吸着測定法）は、ヒト絨毛性ゴナドトロピン（HCG）、卵胞刺激ホルモン（FSH）、テストステロンなどのホルモンレベルの検出と推定に有用です。また、体内のアンフェタミンやコカインの存在など、非医療用薬物の使用も検出します。

世界の感染症の増加は、その特異性と抗体の同定により、ELISA（酵素結合免疫吸着測定法）検査の需要を促進すると予想されています。例えば、世界保健機関（WHO）の2024年世界肝炎報告書によると、ウイルス性肝炎による死亡者数が増加しています。この病気は世界第2位の感染性死因であり、年間130万人が死亡しています。

市場力学：

促進要因と阻害要因

感染症罹患率の増加

感染症罹患率の増加は、ELISA（酵素結合免疫吸着測定法）市場の成長を促進すると予想されます。感染症の増加に伴い、検査室におけるELISA（酵素結合免疫吸着測定法）検査の需要が高まっています。ライム病、ブルセラ症、梅毒、HIV、肝炎などの感染症に対する抗体は、ELISAを用いて検出・測定することができます。

ELISA（酵素結合免疫吸着測定法）は、感染症に関連する抗体、抗原、その他のバイオマーカーを同定するための最も広く使用されている診断法の一つです。感染症の増加に伴い、政府機関、診断センター、その他の検査機関は抗体の検出にELISA（酵素結合免疫吸着測定法）を利用しています。感染症は世界的に増加しています。

例えば、2022年、CDCは州保健機関とコロンビア特別区から約63,000例のライム病患者の報告を受けた。この数字は、定期的な全国サーベイランスで記録された症例を反映したもので、公衆衛生の専門家が疾病を追跡するために用いる手法の一つにすぎないです。別の方法を用いた最近の予測では、米国では毎年約476,000人がライム病と診断され、治療を受けています。この数には、臨床的な疑いに基づいて治療を受けたが、ライム病ではなかった患者も含まれている可能性が高いです。

これらの感染症は、他の疾患とともに、抗体やバイオマーカーを検出するための酵素結合免疫吸着測定キットの利用を必要とします。このように、感染症の罹患率の増加は、ELISA（酵素結合免疫吸着測定法）市場の成長を促進すると予想されます。

代替技術の脅威

ELISA（酵素結合免疫吸着測定法）市場の成長と普及にとって、他の技術による代替の可能性が重要な障害となっています。革新的な診断・研究技術が登場すると、感度の向上、所見の迅速化、コストの低減といったメリットがもたらされ、従来のELISA測定法に取って代わる、あるいは必要性が低下する可能性があります。したがって、上記の要因はELISA（酵素結合免疫吸着測定法）市場を阻害する可能性があります。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 感染症の増加
    • 抑制要因
      • 代替技術の脅威
    • 機会
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析
  • 償還分析
  • 特許分析
  • SWOT分析
  • DMI見解

第6章 検査タイプ別

  • 直接ELISA
  • 間接ELISA
  • サンドイッチELISA
  • 競合ELISA

第7章 製品別

  • キット・試薬
  • ELISA分析装置
    • 自動
    • 半自動

第8章 用途別

  • 創薬
  • 感染症
  • がん検出
  • タンパク質定量化
  • その他

第9章 エンドユーザー別

  • 病院
  • 学術・研究機関
  • 製薬・バイオテクノロジー企業
  • 診断研究所
  • その他

第10章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • 韓国
    • その他アジア太平洋地域
  • 中東・アフリカ

第11章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A分析

第12章 企業プロファイル

  • Thermo Fisher Scientific, Inc.
    • 会社概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な発展
  • American Laboratory Products Company（ALPCO）
  • ZEUS Scientific, Inc.
  • Life Technologies Corporation
  • Bio-Rad Laboratories, Inc.
  • QuidelOrtho Corporation
  • bioMerieux S.A.
  • Gemelli Biotech
  • BD
  • Enzo Biochem Inc.

第13章 付録

目次
Product Code: BT888

Overview

Global enzyme-linked immunosorbent assay market reached US$ 2.14 billion in 2023 and is expected to reach US$ 3.35 billion by 2031, growing at a CAGR of 5.8% during the forecast period 2024-2031.

Enzyme-linked Immunosorbent Assay is useful for detecting and estimating hormone levels such as human chorionic gonadotropin (HCG), follicle-stimulating hormone (FSH), and testosterone, as well as tracking disease outbreaks in communities such as chlamydia or influenza (the flu), and screening blood donations for possible viral components such as HIV. It detects nonmedical drug usage, such as the presence of amphetamines and cocaine in the body.

Rising infectious diseases globally are expected to drive the demand for enzyme-linked immunosorbent assay tests due to their specificity and identification of the antibodies. For instance, according to the World Health Organization's (WHO) 2024 Global Hepatitis Report, the number of deaths from viral hepatitis is rising. The disease is the second leading infectious cause of death in the world, accounting for 1.3 million deaths annually.

Market Dynamics: Drivers & Restraints

Increasing incidence of infectious diseases

The rising incidence of infectious diseases is expected to drive the enzyme-linked immunosorbent assay market growth. With the rising number of infectious diseases, there is a growing demand for enzyme-linked immunosorbent assay tests in laboratories. Antibodies against several infectious diseases such as Lyme disease, brucellosis, syphilis HIV and hepatitis among others can be detected and measured using ELISA.

Enzyme-linked immunosorbent assay is one of the most widely used diagnostic procedures for identifying antibodies, antigens, and other biomarkers linked to infectious illnesses. With the rising number of infectious diseases, government organizations, diagnostic centers and other laboratories depend on enzyme-linked immunosorbent assay for detecting the antibodies. There is a growing number of infectious diseases globally.

For instance, in 2022, the CDC received reports of about 63,000 cases of Lyme disease from state health agencies and the District of Columbia. This figure reflects cases recorded during routine national surveillance, which is simply one method used by public health professionals to track diseases. According to recent predictions utilizing alternative approaches, approximately 476,000 people in the United States will be identified and treated for Lyme disease each year. This number is likely to include patients treated based on clinical suspicion but do not have Lyme disease.

These infectious diseases, along with other diseases, require the utilization of enzyme-linked immunosorbent assay kits to detect antibodies and biomarkers. Thus, the increasing incidence of infectious diseases is expected to drive the Enzyme-Linked Immunosorbent Assay market growth.

Threat of substitution from alternative technologies

The chance of substitution from other technologies is a key obstacle to the growth and adoption of the ELISA (Enzyme-Linked Immunosorbent Assay) market. As innovative diagnostic and research technologies emerge, they provide benefits such as increased sensitivity, faster findings, and lower costs, potentially replacing or reducing the necessity for traditional ELISA assays. Thus, the above factors could hinder the enzyme-linked immunosorbent assay market

Segment Analysis

The global enzyme-linked immunosorbent assay market is segmented based on test type, product, application, end-user and region.

Sandwich ELISA segment is expected to dominate the enzyme-linked immunosorbent assay market share

The sandwich ELISA segment is expected to hold a major portion of the enzyme-linked immunosorbent assay market share. Sandwich ELISAs are the most common type of ELISA. The antigen is sandwiched between two specific antibodies, often known as matched antibody pairs. A microplate is covered with a capture antibody, a sample is added, and the protein of interest adheres to the plate and becomes immobilized.

A sandwich ELISA is more sensitive and robust because the antibody binds to two different sites on the antigen. This improves the binding selectivity of both the primary capture and detection antibodies to the antigen. The sandwich ELISA format is widely utilized due to its sensitivity and specificity.

New sandwich ELISA kits are being introduced into the market by several players which could contribute to the segment's expansion. An increasing number of product launches could help drive the segment's growth. For instance, in June 2024, ArcticZymes Technologies launched its SAN HQ 2.0 ELISA kit. This traditional sandwich ELISA is designed to detect and quantify the SAN HQ 2.0 enzyme in samples taken from the manufacturing stages of a complicated biomanufacturing process, such as the creation of viral vectors.

Thus, the sandwich ELISA segment is expected to hold the major portion of the enzyme-linked immunosorbent assay market share with the increasing innovation of new sandwich ELISA kits and their effectiveness in finding antibodies over other types of tests.

Geographical Analysis

North America is expected to hold a significant position in the enzyme-linked immunosorbent assay market share

North America is expected to hold a dominant position in the enzyme-linked immunosorbent assay market share owing to the increasing innovation of technological products, increasing research and development, the presence of a large number of key market players, and the rising incidence of infectious diseases. The region has highly equipped laboratories and it will invest more in the R&D department.

Several key players introduce a wide range of enzyme-linked immunosorbent assay products and kits with advanced features which could expand the region's market expansion. For instance, on February 13, 2023, Charles River Laboratories International, Inc. launched its first Enzyme-Linked Immunosorbent Assay (ELISA) Kit for the detection and quantitation of residual host cell proteins (HCP) in CHO-based biotherapeutics.

Similarly, on May 24, 2022, Molecular Devices, LLC. unveiled five ready-made workcells for enzyme-linked immunosorbent assay (ELISA) workflows, with automation capabilities ranging from entry-level to advanced. Automation of labor-intensive plate-based assays improves walkaway time, throughput, and reproducibility by lowering the number of common, repetitive, hands-on steps for researchers.

The introduction of advanced instruments and systems will increase the adoption of these enzyme-linked immunosorbent assay products by several laboratories, diagnostic centers and research institutes, which will increase the demand for the products and expand of region's market as well. Several market players in the region invest huge resources in innovating enzyme-linked immunosorbent assay products. Thus, the above factors are expected to drive the region's market growth.

Market Segmentation

By Test Type

  • Direct ELISA
  • Indirect ELISA
  • Sandwich ELISA
  • Competitive ELISA

By Product

  • Kits & Reagents
  • ELISA Analyzers
    • Automated
    • Semi-automated

By Application

  • Drug Discovery
  • Infectious Diseases
  • Cancer Detection
  • Protein Quantification
  • Others

By End-user

  • Hospitals
  • Academic and Research Institutes
  • Pharmaceutical & Biotechnology Companies
  • Diagnostic Laboratories
  • Others

By Region

  • North America
    • The U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Rest of Europe
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa

Competitive Landscape

The major global players in the market include Thermo Fisher Scientific, Inc., American Laboratory Products Company (ALPCO), ZEUS Scientific, Inc., Life Technologies Corporation, Bio-Rad Laboratories, Inc., QuidelOrtho Corporation, Biomerieux S.A., Gemelli Biotech, BD

and Enzo Biochem Inc. among others.

Why Purchase the Report?

  • To visualize the global enzyme-linked immunosorbent assay market segmentation based on test type, product, application, end-user, and region as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of enzyme-linked immunosorbent assay market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as Excel consisting of key products of all the major players.

The global enzyme-linked immunosorbent assay market report would provide approximately 53 tables, 47 figures, and 176 pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Test Type
  • 3.2. Snippet by Product
  • 3.3. Snippet by Application
  • 3.4. Snippet by End-user
  • 3.5. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing incidence of infectious diseases
    • 4.1.2. Restraints
      • 4.1.2.1. Threat of substitution from alternative technologies
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Reimbursement Analysis
  • 5.6. Patent Analysis
  • 5.7. SWOT Analysis
  • 5.8. DMI Opinion

6. By Test Type

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
    • 6.1.2. Market Attractiveness Index, By Test Type
  • 6.2. Direct ELISA*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Indirect ELISA
  • 6.4. Sandwich ELISA
  • 6.5. Competitive ELISA

7. By Product

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 7.1.2. Market Attractiveness Index, By Product
  • 7.2. Kits & Reagents*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. ELISA Analyzers
    • 7.3.1. Automated
    • 7.3.2. Semi-automated

8. By Application

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.1.2. Market Attractiveness Index, By Application
  • 8.2. Drug Discovery*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Infectious Diseases
  • 8.4. Cancer Detection
  • 8.5. Protein Quantification
  • 8.6. Others

9. By End-user

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
    • 9.1.2. Market Attractiveness Index, By End-user
  • 9.2. Hospitals*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Academic and Research Institutes
  • 9.4. Pharmaceutical & Biotechnology Companies
  • 9.5. Diagnostic Laboratories
  • 9.6. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
      • 10.2.2.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
      • 10.2.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
      • 10.2.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
      • 10.2.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.3.1. The U.S.
      • 10.2.3.2. Canada
      • 10.2.3.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
      • 10.3.2.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
      • 10.3.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
      • 10.3.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
      • 10.3.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.3.1. Germany
      • 10.3.3.2. UK
      • 10.3.3.3. France
      • 10.3.3.4. Italy
      • 10.3.3.5. Spain
      • 10.3.3.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
      • 10.4.2.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
      • 10.4.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
      • 10.4.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.4.1. Brazil
      • 10.4.4.2. Argentina
      • 10.4.4.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
      • 10.5.2.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
      • 10.5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
      • 10.5.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.4.1. China
      • 10.5.4.2. India
      • 10.5.4.3. Japan
      • 10.5.4.4. South Korea
      • 10.5.4.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
      • 10.6.2.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
      • 10.6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
      • 10.6.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Thermo Fisher Scientific, Inc.*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
  • 12.2. American Laboratory Products Company (ALPCO)
  • 12.3. ZEUS Scientific, Inc.
  • 12.4. Life Technologies Corporation
  • 12.5. Bio-Rad Laboratories, Inc.
  • 12.6. QuidelOrtho Corporation
  • 12.7. bioMerieux S.A.
  • 12.8. Gemelli Biotech
  • 12.9. BD
  • 12.10. Enzo Biochem Inc.

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us